Viyash Scientific Q1 FY27 Earnings Call Transcript Released
Viyash Scientific reported strong Q1 FY27 results with revenue at ₹946 crore (up 20% YoY) and PAT at ₹79 crore (more than doubled YoY). EBITDA rose 59% to ₹205 crore, with margins at 21.6%. Net debt reduced to ₹86 crore. The company is set to acquire Bio For Life in Italy, strengthening its companion animal health segment.
The strong financial performance, significant debt reduction, and strategic acquisition indicate a positive impact on the company's financial health and future growth prospects.
The company reported significant year-on-year growth in revenue, EBITDA, and profit after tax, along with a substantial reduction in net debt. The acquisition of Bio For Life is a strategic positive step. Management commentary indicates confidence in continued growth.
Viyash Scientific Limited (formerly Sequent Scientific Limited) has released the transcript of its earnings call for the quarter ended June 30, 2026. The call, held on August 12, 2026, featured insights from Managing Director & Group CEO Dr. Haribabu Bodepudi, Executive Director & CEO of Animal Health Mr. Rajaram Narayanan, and CFO Mr. Ramakant Singani.
Dr. Bodepudi highlighted a strong Q1 FY27 performance with revenue from operations at ₹946 crore, a 20% year-on-year growth. EBITDA stood at ₹205 crore, up 59% year-on-year, with margins expanding to 21.6%. Profit after tax more than doubled year-on-year to ₹79 crore. The company's net debt has significantly reduced to ₹86 crore, with net debt to EBITDA at 0.1x.
The Animal Health Formulation business showed robust growth across all regions, with a particular surge of 60% in the domestic market. The Human Formulation business in the US also grew by 60%, driven by a shift towards backward-integrated, complex products. API revenue was flat quarter-on-quarter due to raw material price volatility but is expected to see strong recovery in the current quarter.
The company is proceeding with the acquisition of Bio For Life in Italy, which is expected to close in the coming months. This strategic move aligns with Viyash's focus on companion animal health and will provide direct market access in Italy. Investments are also being made in R&D and manufacturing capabilities.
CFO Mr. Ramakant Singani detailed the financials, noting a 19.5% year-on-year revenue growth to ₹946 crore and an improved gross margin of 54.1%. Adjusted EBITDA increased by 59.2% to ₹205 crore. Profit before tax rose by 132% to ₹112 crore, and profit after tax increased by 115% to ₹79 crore. The company also granted ₹1.3 crore worth of employee stock options during the quarter, resulting in an incremental expense of ₹19 crore.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.